Agenus posts corporate presentation spotlighting botensilimab-balstilimab neoadjuvant strategy in MSS colon cancerPUBT·2 hours agoAGEN+12.07%
Mid-Cap Tech and Healthcare Face Critical Tests: From Delisting Risks to Mega FinancingsGlobal Report·Jul 26 at 04:15 AMCYCU+340.41%BJDX+1.64%
M&A, Poison Pills, and Capital Restructuring Drive US Mid-Cap RealignmentsGlobal Report·Jul 25 at 04:13 AMDKL-0.34%CISS+5.34%
Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focusrttnews·Jul 23 at 10:24 PMNVCR+0.53%MEDP-0.78%
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 | AGEN Stock NewsStockTitan·Jul 17 at 01:28 AMAGEN+12.07%
Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focusrttnews·Jul 13 at 09:35 PMAGEN+12.07%SI-0.34%
Oracle, Twin Vee PowerCats, Agenus, Micron Technology and SanDisk: Why These 5 Stocks Are on Investors' Radars Todaybenzinga_article·Jul 13 at 08:34 PMVEEE-1.08%MU+15.57%
AGEN: Secured $340M to advance Phase 3 BOT + BAL trial in MSS colon cancer, targeting major marketQuartr·Jul 13 at 06:04 AMAGEN+12.07%
Agenus Jumps 99% on $340M Raise for Phase 3 Colon Cancer TrialUS Stock Market Update·Jul 13 at 12:51 PMAGEN+12.07%
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga_article·Jul 13 at 12:05 PMBIVI+14.52%QTTB+3.83%
Agenus soars 107% on $340 million private placement for drug trialsUS Stock Market Update·Jul 13 at 10:22 AMAGEN+12.07%
STOCKS | MGM Rises on Takeover Bid Report; SK Hynix Falls on Memory PullbackCoinLive·Jul 13 at 09:45 AMAGEN+12.07%MGM+0.39%